Publications

Authors:

Salvagno, GIAN LUCA; Henry, Brandon M.; Pighi, Laura; DE NITTO, Simone; Lippi, Giuseppe

Title:

Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster

Year:

2022

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

Elettronico

Referee:

Sì

Name of journal:

EJIFCC

ISSN of journal:

1650-3414

N° Volume:

33

Number or Folder:

2

Page numbers:

166-174

Keyword:

COVID-19; SARS-CoV-2; antibodies; immune response; vaccination.

Short description of contents:

Background: In this serosurveillance study, we investigated the variation of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in healthcare workers receiving primary BNT162b2 vaccination and homologous booster. Methods: A total number of 524 subjects (median age, 46 years; 65.3% females), were studied. All received primary BNT162b2 vaccination (two doses) and homologous booster (one dose) >8 months after completing the primary cycle. Blood samples were collected before the first and second vaccine doses, at 1, 3 and 6 months after the second dose, as well as before and 1 month after booster. Total anti-SARS-CoV-2 neutralizing antibodies were assayed with Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay. Results: Overall, 65.1% subjects were baseline (i.e., pre-vaccination) SARS-CoV-2 seronegative and always tested SARS-CoV-2 negative ("N/N"), 16.2% were baseline SARS-CoV-2 seronegative but tested SARS-CoV-2 positive after receiving the vaccine booster dose ("N/P"), whilst 18.7% were baseline SARS-CoV-2 seropositive and always tested SARS-CoV-2 negative afterwards ("P/N"). All groups displayed a similar trend of total anti-SARS-CoV-2 S antibodies throughout the study period, though the P/N cohort exhibited higher values compared to the other two groups until receiving the booster, after which the levels become similar in all cohorts. Significant differences in total anti-SARS-CoV-2 S antibodies values were not found between N/N and N/P groups, neither 1 month after booster. The rate of subjects with protective antibodies values become 100% in all groups after booster. Conclusions: Although baseline seropositivity is associated with more pronounced humoral immune response following primary vaccination compared to never infected subjects, SARS-CoV-2 infection after booster does not significantly foster antibody titers.

Web page:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562482/

Product ID:

130008

Handle IRIS:

11562/1077046

Last Modified:

November 4, 2023

Bibliographic citation:

Salvagno, GIAN LUCA; Henry, Brandon M.; Pighi, Laura; DE NITTO, Simone; Lippi, Giuseppe, Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster «EJIFCC» , vol. 33 , n. 2 , 2022 , pp. 166-174

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo